Business Standard

Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%

The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.

Lab test, research, r&d, chemicals, medical research, vaccine, health, pharma
Web Exclusive Premium

Pharma stocks

Avdhut Bagkar Mumbai
Shares of pharmaceuticals companies were seen in demand on Monday, with the likes of Aurobindo Pharma and Glenmark surging 5 per cent and 4 per cent, respectively.

Other stocks like Strides Pharma Science,  Laurus Labs and Granules India also gained over 3 per cent each. Most stocks in Nifty Pharma index were trading with the positive bias.

The Nifty Pharma index had declined 17 per cent decline from its all-time high of 14,398 level in the recent sell-off. The index is likely to see some upside in the near term, with more promising returns see in select pharma shares.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in